Dr. Friedrich von Bohlen und Halbach
Dr. Friedrich von Bohlen und Halbach is managing partner and co-founder of dievini Hopp BioTech Holding GmbH & Co. KG., the company managing the life science activities and investments of Dietmar Hopp, co founder of SAP, and his family. Friedrich von Bohlen holds a diploma in biochemistry from the University of Zurich and a PhD in neurobiology from the Swiss Federal Institute of Technology (ETH) in Zurich. He held various positions at Fresenius AG, FAG Kugelfischer KGaA and WASAG Chemie AG. In 1997 he founded LION bioscience AG (now Sygnis AG), whose CEO he was for seven years. He is chairman of the Board of Apogenix AG, CureVac AG and Novaliq GmbH, as well as board member of AC Immune SA, immatics biotechnologies GmbH, Wilex AG and member of the evaluation board of Wyss Translational Center Zurich and managing director of Molecular Health GmbH.